Get started
Author

Stefanie Brehmer

Observed names: Brehmer, Stefanie, S Brehmer, S. Brehmer, STEFANIE BREHMER, Stefanie, Brehmer
Observed institutions: Goethe University Frankfurt, Montreal Neurological Institute and Hospital, The University of Texas MD Anderson Cancer Center, University of Bonn, University of Freiburg, University of Mannheim, German Cancer Research Center, University of Cologne, Loyola University Chicago, Heidelberg University, McGill University Health Centre, University Hospital Regensburg, Evangelisches Krankenhaus Bielefeld, Essen University Hospital, University Medical Centre Mannheim, Loyola Medicine, Medizinische Fakultät Mannheim, Deutsches Konsortium für Translationale Krebsforschung, Freie Universität Berlin, Charité – Universitätsmedizin Berlin, Leipzig University
ORCID: 0000-0001-9113-9865
Observed ORCID: 0000-0001-9113-9865
OpenAlex ID: A5006650814
DNA methylation-based classification of central nervous system tumours
2018 · David Capper, David T. W. Jones, et al. · Nature · 3,145
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
2017 · Felix Sahm, Daniel Schrimpf, et al. · The Lancet Oncology · 894
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
2019 · Ulrich Herrlinger, Theophilos Tzaridis, et al. · The Lancet · 614
PDF
TERT Promoter Mutations and Risk of Recurrence in Meningioma
2015 · Felix Sahm, Daniel Schrimpf, et al. · JNCI Journal of the National Cancer Institute · 420
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
2016 · Ulrich Herrlinger, Niklas Schäfer, et al. · Journal of Clinical Oncology · 202
AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry
2013 · Felix Sahm, Juliane Bissel, et al. · Acta Neuropathologica · 106
Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study
2019 · Christopher P. Cifarelli, Stefanie Brehmer, et al. · Journal of Neuro-Oncology · 62
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial
2018 · Frank A Giordano, Stefanie Brehmer, et al. · Neurosurgery · 58
INTRAGO: intraoperative radiotherapy in glioblastoma multiforme – a Phase I/II dose escalation study
2014 · Frank A Giordano, Stefanie Brehmer, et al. · BMC Cancer · 57
PDF
Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
2019 · Johannes Weller, Theophilos Tzaridis, et al. · The Lancet Oncology · 49
PDF
Intraoperative radiotherapy for glioblastoma: an international pooled analysis
2019 · Gustavo R. Sarria, Elena Sperk, et al. · Radiotherapy and Oncology · 32
PDF
Multicentric Assessment of Safety and Efficacy of Combinatorial Adjuvant Brain Metastasis Treatment by Intraoperative Radiation Therapy and Immunotherapy
2024 · Julian P. Layer, Ehab Shiban, et al. · International Journal of Radiation Oncology*Biology*Physics · 23
PDF
ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
2017 · Ulrich Herrlinger, Theophilos Tzaridis, et al. · Neuro-Oncology · 23
Molecular features of glioblastomas in long-term survivors compared to short-term survivors—a matched-pair analysis
2022 · Vivien N. Sommerlath, Daniel Buergy, et al. · Radiation Oncology · 20
PDF
Boswellia serrata for the Management of Radiation-Induced Cerebral Edema and Necrosis: A Systematic Meta-Narrative Review of Clinical Evidence
2025 · Cas Stefaan Dejonckheere, Davide Scafa, et al. · Advances in Radiation Oncology · 18
Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years
2017 · Yvonne Schweizer, Zsolt Meszaros, et al. · Journal of Neuropathology & Experimental Neurology · 17
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis
2015 · Grit Welzel, Julian Gehweiler, et al. · Journal of Neuro-Oncology · 16
23Na-MRI of recurrent glioblastoma multiforme after intraoperative radiotherapy: technical note
2014 · Stefan Haneder, Frank A. Giordano, et al. · Neuroradiology · 14
Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations: Scientific correspondence
2010 · S. Brehmer, S. Pusch, et al. · Neuropathology and Applied Neurobiology · 12
Opportunities and Alternatives of Modern Radiation Oncology and Surgery for the Management of Resectable Brain Metastases
2023 · Christian D. Diehl, Frank A. Giordano, et al. · Cancers · 11
PDF
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
2023 · J. Weller, N. Schäfer, et al. · Journal of Neuro-Oncology · 11
PDF
Study Protocol: Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma (Gamma-GBM)
2018 · Stefanie Brehmer, Mario Alexander Grimm, et al. · Neurosurgery · 11
Intraoperative radiotherapy (IORT)—a resurrected option for treating glioblastoma?
2014 · Frank A. Giordano, Yasser Abo‐Madyan, et al. · Translational Cancer Research · 10
Longitudinal MRI findings in patients with newly diagnosed glioblastoma after intraoperative radiotherapy
2019 · Alex Förster, Johannes Böhme, et al. · Journal of Neuroradiology · 9
Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial
2026 · Frank Anton Giordano, Oliver Ganslandt, et al. · The Lancet Oncology · 7
Works count: 73
Citation count: 5,877
H-index: 16
I10-index: 23
Year
Topic
Type